(NASDAQ: CRSP) Crispr Therapeutics Ag's forecast annual revenue growth rate of 75.4% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.39%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.86%.
Crispr Therapeutics Ag's revenue in 2024 is $202,227,000.On average, 12 Wall Street analysts forecast CRSP's revenue for 2024 to be $5,467,880,912, with the lowest CRSP revenue forecast at $86,871,521, and the highest CRSP revenue forecast at $39,083,667,706. On average, 11 Wall Street analysts forecast CRSP's revenue for 2025 to be $40,113,435,905, with the lowest CRSP revenue forecast at $5,989,450,711, and the highest CRSP revenue forecast at $282,059,905,664.
In 2026, CRSP is forecast to generate $98,743,281,040 in revenue, with the lowest revenue forecast at $9,610,119,444 and the highest revenue forecast at $463,578,800,810.